Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device.

Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver INO-4800 directly into the skin. It may also be used to deliver a potential COVID-19 vaccine.

The small, portable, hand-held device that runs in “AA” batteries is designed to deliver the INO-4800 vaccine where it prompts the body’s immune system to drive an immune response. It is currently in the midst of a U.S. Phase I clinical trial, for which results will be available later this month. A Phase II/III efficacy trial is slated to begin this month or next.

Plymouth Meeting, Pa.-based Inovio said in a news release that its San Diego manufacturing facility has produced initial quantities of the device and displayed capabilities for scale-…

Read more
  • 0

HHS taps Pfizer to produce millions of COVID-19 vaccine doses

[Photo by Fusion Medical Animation on Unsplash]

Two U.S. government agencies today announced an agreement with Pfizer (NYSE:PFE) for production and delivery of 100 million doses of a COVID-19 vaccine.

The U.S. Dept. of Health and Human Services, along with the U.S. Defense Dept., agreed to the large-scale production and U.S. delivery deal once Pfizer’s vaccine is successfully manufactured and approved. In addition to the 100 million doses initially agreed upon. the U.S. government will be able to acquire an additional 500 million doses.

Pfizer will deliver the initial 100 million doses if the vaccine candidate receives FDA emergency use authorization (EUA) or licensure once a Phase 3 clinical trial is complete, demonstrating safety and efficacy in the fight against COVID-19. The timing of the agreement is designed to allow quick shipment once approval is garnered in an effort to meet the U.S. gov…

Read more
  • 0

HHS spending $347m to boost supply of COVID-19 vaccine, treatment vials

The U.S. Dept. of Health & Human Services (HHS) and Dept. of Defense (DoD) announced a joint effort to increase manufacturing for vials earmarked for COVID-19-related drugs and vaccines.

The Biomedical Advanced Research and Development Authority (BARDA), as part of HHS, collaborated with DoD to provide funding for U.S.-based companies Corning Inc. and SiO2 Materials Science.

Get the full story at our sister site, Pharmaceutical Processing World.

Read more
  • 0